<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2306-4102</journal-id>
<journal-title><![CDATA[Acta ortopédica mexicana]]></journal-title>
<abbrev-journal-title><![CDATA[Acta ortop. mex]]></abbrev-journal-title>
<issn>2306-4102</issn>
<publisher>
<publisher-name><![CDATA[Colegio Mexicano de Ortopedia y Traumatología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2306-41022025000100008</article-id>
<article-id pub-id-type="doi">10.35366/118846</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eficacia de la dosis única de ácido tranexámico prequirúrgica para prevenir la pérdida de sangre en el reemplazo articular total de cadera y rodilla]]></article-title>
<article-title xml:lang="en"><![CDATA[Efficacy of single-dose preoperative tranexamic acid to prevent blood loss in total hip and knee joint replacement]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Campos-Flores]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lameiro-Sánchez]]></surname>
<given-names><![CDATA[FP]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Galicia-Zamalloa]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado Hospital Regional Puebla Servicio de Traumatología y Ortopedia]]></institution>
<addr-line><![CDATA[Puebla ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto de Seguridad y Servicios Sociales de los Trabajadores al Servicio de los Poderes del Estado de Puebla Servicio de Traumatología y Ortopedia ]]></institution>
<addr-line><![CDATA[Puebla ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>02</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>02</month>
<year>2025</year>
</pub-date>
<volume>39</volume>
<numero>1</numero>
<fpage>8</fpage>
<lpage>12</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S2306-41022025000100008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S2306-41022025000100008&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S2306-41022025000100008&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  el sangrado trans y postquirúrgico en las artroplastías totales de cadera y rodilla es la preocupación más frecuente del cirujano. Existen múltiples estrategias para disminuir esta tasa de transfusión, como son el empleo de ácido tranexámico, del cual aún no existe un consenso establecido de la dosis idónea.  Objetivo:  evaluar la eficacia y seguridad de una dosis única de ácido tranexámico prequirúrgica para reducir la pérdida de sangre en la artroplastía total de cadera y rodilla.  Material y métodos:  se analizó un total de 60 pacientes. Los participantes fueron distribuidos de forma aleatoria en dos grupos: grupo control al cual no se le administro ácido tranexámico y un grupo experimental al que se le administró 1 g de ácido tranexámico 30 minutos antes de iniciar el evento quirúrgico. Se analizó la pérdida de sangre, la velocidad y el volumen de transfusión de sangre, así como el nivel de hemoglobina.  Resultados:  la pérdida de hemoglobina en el grupo control fue 3.5 ± 1.4 g/dl, en comparación con el grupo experimental, donde fue 2.5 ± 1.5 g/dl; p = 0.006. La pérdida del hematocrito fue de 10.6% ± 3.5 para el grupo control, en comparación con 8% ± 4.9 para el grupo experimental; p = 0.02. La transfusión sanguínea sólo se realizó en tres pacientes (5%), dos del grupo control y uno del grupo experimental (p = 0.4).  Conclusión:  la dosis intravenosa de 1 g prequirúrgico de ácido tranexámico disminuye la pérdida de hemoglobina de pacientes sometidos a reemplazo total articular de cadera y rodilla.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  transfusion-related complications are a major concern for surgeons performing total hip and knee arthroplasty (THA and TKA). Several strategies have been implemented to reduce transfusion rates, including the use of tranexamic acid (TXA), whose optimal dosage remains a matter of debate.  Objective:  to evaluate the efficacy and safety of a single pre-surgical dose of TXA in reducing blood loss in THA and TKA.  Material and methods:  sixty patients were enrolled. Patients were randomly assigned to either a control group (no TXA) or an experimental group (1 g TXA 30 minutes before surgery). Blood loss, blood transfusion rate and volume, and hemoglobin levels were analyzed.  Results:  hemoglobin loss in the control group was 3.5 ± 1.4 g/dl compared to 2.5 ± 1.5 g/dl in the experimental group (p = 0.006). Hematocrit loss was 10.6% ± 3.5 in the control group and 8% ± 4.9 in the experimental group (p = 0.02). Blood transfusion was only required in 3 patients (5%): 2 in the control group and 1 in the experimental group (p = 0.4).  Conclusions:  a single pre-surgical intravenous dose of 1 g TXA reduces hemoglobin loss in patients undergoing THA and TKA.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[transfusión sanguínea]]></kwd>
<kwd lng="es"><![CDATA[pérdida de sangre]]></kwd>
<kwd lng="es"><![CDATA[artroplastía total de cadera]]></kwd>
<kwd lng="es"><![CDATA[artroplastía total de rodilla]]></kwd>
<kwd lng="es"><![CDATA[ácido tranexámico]]></kwd>
<kwd lng="en"><![CDATA[blood transfusion]]></kwd>
<kwd lng="en"><![CDATA[blood loss]]></kwd>
<kwd lng="en"><![CDATA[total hip arthroplasty]]></kwd>
<kwd lng="en"><![CDATA[total knee arthroplasty]]></kwd>
<kwd lng="en"><![CDATA[tranexamic acid]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[BX]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gao]]></surname>
<given-names><![CDATA[CX]]></given-names>
</name>
<name>
<surname><![CDATA[Zhong]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multiple intravenous tranexamic acid doses in total knee arthroplasty in patients with rheumatoid arthritis: a randomized controlled study]]></article-title>
<source><![CDATA[BMC Musculoskelet Disord]]></source>
<year>2021</year>
<volume>22</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>425</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Feldmann]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Wulf]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wiesmann]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tranexamic acid prophylaxis in hip and knee joint replacement]]></article-title>
<source><![CDATA[Dtsch Arztebl Int]]></source>
<year>2017</year>
<volume>114</volume>
<numero>48</numero>
<issue>48</issue>
<page-range>824-30</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Jun]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[WK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Natural course of hemoglobin level after total knee arthroplasty and the benefit of tranexamic acid injection in the joint]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2021</year>
<volume>100</volume>
<numero>35</numero>
<issue>35</issue>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Ge]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of a single dose and an additional dose of tranexamic acid in reduction of blood loss in total knee arthroplasty]]></article-title>
<source><![CDATA[J Arthroplasty]]></source>
<year>2017</year>
<volume>32</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>2108-12</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[CX]]></given-names>
</name>
<name>
<surname><![CDATA[Yao]]></surname>
<given-names><![CDATA[YF]]></given-names>
</name>
<name>
<surname><![CDATA[Lv]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Jing]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and safety of postoperative intravenous tranexamic acid in total knee arthroplasty: a prospective randomized controlled study]]></article-title>
<source><![CDATA[Orthop Surg]]></source>
<year>2021</year>
<volume>13</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2227-35</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Poeran]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Zubizarreta]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Mazumdar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Galatz]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Moucha]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety of tranexamic acid in hip and knee arthroplasty in high-risk patients]]></article-title>
<source><![CDATA[Anesthesiology]]></source>
<year>2021</year>
<volume>135</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>57-68</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Krebs]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[VanWagner]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Marchewka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Faraj]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Vitale]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tranexamic acid in the treatment of hip fractures: a clinical review]]></article-title>
<source><![CDATA[Spartan Med Res J]]></source>
<year>2019</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>7026</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>CRASH-2 trial collaborators</collab>
<article-title xml:lang=""><![CDATA[Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shakur]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Roberts]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bautista]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Caballero]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Coats]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet]]></source>
<year>2010</year>
<volume>376</volume>
<numero>9734</numero>
<issue>9734</issue>
<page-range>23-32</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balachandar]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Abuzakuk]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is there an optimal timing of administration of single-dose intravenous tranexamic acid in bilateral total knee arthroplasty? A comparison between preoperative and intraoperative dose]]></article-title>
<source><![CDATA[J Orthop Surg (Hong Kong)]]></source>
<year>2019</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>2309499019880915</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sanz-Reig]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Parra Ruiz]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ferrández Martínez]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Martínez López]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Dosis única intravenosa de ácido tranexámico como medida de ahorro transfusional en prótesis total primaria de rodilla [Single intravenous tranexamic acid dose to reduce blood loss in primary total knee replacement]]]></article-title>
<source><![CDATA[Rev Esp Cir Ortop Traumatol]]></source>
<year>2016</year>
<volume>60</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>106-12</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilde]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Copp]]></surname>
<given-names><![CDATA[SN]]></given-names>
</name>
<name>
<surname><![CDATA[McCauley]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Bugbee]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[One dose of intravenous tranexamic acid is equivalent to two doses in total hip and knee arthroplasty]]></article-title>
<source><![CDATA[J Bone Joint Surg Am]]></source>
<year>2018</year>
<volume>100</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1104-9</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
